Danaher (NYSE:DHR) Price Target Lowered to $311.00 at Royal Bank of Canada

Danaher (NYSE:DHR) had its price target lowered by Royal Bank of Canada from $333.00 to $311.00 in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has an outperform rating on the conglomerate’s stock.

Other research analysts also recently issued reports about the company. Bank of America raised their price objective on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Stifel Nicolaus boosted their price objective on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday. Stephens reiterated an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research note on Wednesday. KeyCorp boosted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, The Goldman Sachs Group boosted their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $287.28.

Danaher Price Performance

Shares of NYSE:DHR opened at $256.00 on Wednesday. The business has a fifty day simple moving average of $270.43 and a 200 day simple moving average of $260.43. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher has a 1 year low of $182.09 and a 1 year high of $281.70. The firm has a market cap of $189.62 billion, a price-to-earnings ratio of 43.39, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue was up 3.1% compared to the same quarter last year. During the same period in the previous year, the company earned $2.02 earnings per share. As a group, sell-side analysts predict that Danaher will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Insider Activity

In related news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Linda Filler sold 3,928 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.50, for a total value of $1,097,876.00. Following the transaction, the director now owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,059 shares of company stock valued at $8,400,897 over the last three months. 11.10% of the stock is owned by insiders.

Institutional Trading of Danaher

Several institutional investors and hedge funds have recently made changes to their positions in DHR. Benjamin Edwards Inc. grew its stake in shares of Danaher by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock worth $538,000 after purchasing an additional 38 shares during the period. Wedge Capital Management L L P NC raised its position in shares of Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 38 shares during the period. Patrick M Sweeney & Associates Inc. boosted its stake in Danaher by 3.4% during the 2nd quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock worth $307,000 after acquiring an additional 40 shares during the last quarter. Trust Co of Kansas grew its holdings in Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after purchasing an additional 40 shares during the period. Finally, Abacus Planning Group Inc. increased its stake in Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after purchasing an additional 40 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.